Rua completes first step to Polish market entry

Rua Bioscience (NZX: RUA ) is pleased to announce that its first medicinal cannabis dossier for the Polish market has now been submitted to the regulatory authority responsible for licencing cannabis-based medicines in Poland (the Polish Office for Registration of Medicinal Products (URPL)).

The dossier, prepared by the regulatory team from Rua and its Australian manufacturing partner Cann Group, provides detailed information to demonstrate the quality of the product, including information about the cultivation of the cannabis, and the subsequent manufacturing process, quality checks, and stability of the product.

The submission of the dossier is the first step in accessing the high-value Polish market, triggering what is anticipated to be a highly complex, but ultimately rewarding, 12- to 18-month process.

The Polish medicinal cannabis market was established in 2017 and is described as one of the largest and fastest-growing markets in Europe. The market shows consistent double-digit growth and, according to proprietary data, could be worth NZ$92m by the close of 2023.

Rua Bioscience CEO, Paul Naske, says “Poland is a very tricky market to enter but presents a significant opportunity for those with access. Our work with the specialist sales and marketing team at Motagon has positioned us as an early mover, and we expect their European-based support and regulatory expertise will be invaluable as we progress our submission.”

Last week, Rua announced it would accelerate its export-focused strategy investigating the commercial potential of markets such as Poland, Czechia, the United Kingdom, and Australia.

“As we enter high-value international markets, steps like this will become more commonplace. But the submission of our first dossier in Poland demonstrates a tangible commitment to our export strategy and to create a sustainable international business.”

Ends

Rua completes first step to Polish market entry

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million
SML - Resignation of Synlait Director
FBU - Sale of Laminex Cheltenham property
CVT - Comvita Achieves Minimum Capital Raise Requirement
Devon Funds Morning Note - 04 May 2026
MEL - Meridian joins global ranks of sustainable companies
May 5th Morning Report